Amyloid heart disease: A brief review of treatment options

Postgraduate Medical Journal

Volumn 88, Issue 1046, 2012, Pages 700-705

  Dubrey, Simon W ^a  

^a HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREALBUMIN; SMALL INTERFERING RNA; TAFAMIDIS; THALIDOMIDE; VINCRISTINE;

AMYLOIDOSIS; ANTISENSE THERAPY; AUTOMATED EXTERNAL DEFIBRILLATOR; BONE MARROW TOXICITY; CARDIOTOXICITY; COMPRESSION STOCKING; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FAMILIAL AMYLOIDOSIS; GENE MUTATION; GENETIC COUNSELING; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; ISOLATED ATRIAL AMYLOIDOSIS; KIDNEY TRANSPLANTATION; LEUKEMIA; LIGHT CHAIN AMYLOIDOSIS; LIVER TRANSPLANTATION; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SENILE SYSTEMIC AMYLOIDOSIS;

AMYLOIDOSIS; AMYLOIDOSIS, FAMILIAL; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 84870515187     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2012-130854     Document Type: Review

References (33)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Lin G, Dispenzieri A, Grogan M, et al. Outcomes of implantable defibrillators in patients with cardiac amyloidosis. Amyloid 2010;17:166a.
3. Anesi E, Palladini G, Perfetti V, et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001;111:243-4.
4. Kristen AV, Perz JB, Schonland SO, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. Eur J Heart Fail 2007;9:617-24.
5. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002;416:507-11.
6. Sanchorawala V, Seldin DC, Magnani B, et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36:597-600.
7. Palladini G, Dispenzieri A, Gertz MAA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010;116:1364.
8. Ruberg FL, Applebaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light chain cardiac amyloidosis. Am J Cardiol 2009;103:544-9.
9. Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787-8.
10. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Int Med 2004;140:85-93.
11. Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23:1142-53.
12. Sack FU, Kristen A, Goldschmidt H, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33:257-62.
13. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant 2008;27:823-9.
14. Dubrey SW, Reece DE, Sanchorawala V, et al. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 2011;104:957-70.
15. Mikhael J, Jiminez-Zepeda VH, Reeder CB, et al. Cylcophosphamide-bortezomibdexamethasone (CYBORD) is highly effective in producing rapid and complete responses in patients with AL amyloidosis not eligible for transplantation. Amyloid 2010;17:157.
16. Herlenius G, Wilczek HE, Larsson M, et al. Familial Amyloidotic Polyneuropathy World transplant registry. Ten years of International experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial Amyloidotic World Transplant Registry. Transplantation 2004;77:64-71.
17. Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997;64:74-80.
18. Gillmore JD, Booth DR, Rela M, et al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. QJM 2000;93:269-75.
19. Gillmore JD, Stangou AJ, Lachmann HJ, et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 2006;6:2342-7.
20. Pilato E, Dell'Amore A, Botta L, et al. Combined heart and liver transplantation for amyloidotic neuropathy. Eur J Cardiothorac Surg 2007;32:180-2.
21. Coelho T, Maia L, Martins da Silva A, et al. Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid 2010;17: OP-066.
22. Oza VB, Smith C, Raman P, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 2002;45:321-32.
23. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004;84:545-52.
24. Sekijima Y, Kelly JW, Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-30.
25. Benson MD, Pandey S, Witchell D, et al. Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2010;17:OP-028.
26. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9.
27. Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
28. Dubrey S, Cha K, Simms RW, et al. Echocardiographic and electrocardiographic features of cardiac involvement in secondary (AA) amyloidosis. Am J Cardiol 1996;77:313-15.
29. Hawkins PN. Systemic amyloidosis: getting to the heart of the matter. Br J Hosp Med 2010;71:66-7.
30. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
31. Comenzo RL. How I treat amyloidosis. Blood 2009;114:3147-57.
32. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010;52:347-61.
33. Dubrey SW, Comenzo RL. Amyloid heart disease: current and future therapies. QJM. Published Online First 5 January 2012. doi:10.1093/qjmed/hcr259